Sugi Predict

Sugi Predict / Compounds / SCHEMBL30483960

SCHEMBL30483960

SCHEMBL30483960

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)[C@@H](C)CC)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 11/20 0.52
▸ VIPR2 P41587 6/20 0.51
▸ VIPR1 P32241 3/20 0.51
▸ BACE1 P56817 1/20 0.50
▸ F2 P00734 1/20 0.49
▸ KEAP1 Q14145 1/20 0.49
▸ SCTR P47872 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30692675 0.89 GLP1R (0.56) GLP1RVIPR2VIPR1BACE1
SCHEMBL31678886 0.87 GLP1R (0.65) GLP1RSCTR
SCHEMBL29461455 0.87 GLP1R (0.56) GLP1RVIPR2VIPR1SCTR
SCHEMBL29797106 0.87 KEAP1 (0.54) GLP1RVIPR2VIPR1BACE1KEAP1
SCHEMBL31182941 0.87 GLP1R (0.65) GLP1RVIPR1SCTR
SCHEMBL29416080 0.87 GLP1R (0.56) GLP1RVIPR2VIPR1SCTR
SCHEMBL29541008 0.86 VIPR2 (0.47) GLP1RVIPR2VIPR1
SCHEMBL29541058 0.86 VIPR2 (0.47) GLP1RVIPR2VIPR1
SCHEMBL31182723 0.86 GLP1R (0.67) GLP1RSCTR
SCHEMBL30262179 0.85 GLP1R (0.51) GLP1RVIPR2VIPR1SCTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230127047-A1 SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES ANTAROS MEDICAL AB (SE) 2023-04-27 — — US claimed
US-20230127047-A1 SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES ANTAROS MEDICAL AB (SE) 2023-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127047-A1 SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES GIPR, GRPR, GLP1R GLP1R 3/4885VIPR2 16/4885VIPR1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback